ERBB2 and breast cancer: Moreover, according to the Fulvestrant and Anastrozole Compared in Hormonal Therapy Naive Advanced Breast Cancer (FALCON) trial, comparing F with anastrozole in the same setting, the single-agent F therapy may be a further reasonable option for HR+/HER2− MBC patients who are ET-naïve, especially those with the non-visceral disease.